Research.
[ 68 5), and hypoxia-inducible factor 2α (HIF2A) (6) have been evaluated and often found to be associated with the presence of multiple and metastatic PHEOs/PGLs.
More than 40% of metastatic PHEOs/PGLs are related to succinate dehydrogenase subunit B (SDHB) mutation carriers (7) , who are at high risk for developing metastatic disease.
Some studies show a risk of up to 90% (8) , with an only 36% 5-year probability of survival after diagnosis of metastatic disease (7) . Proper staging and early detection of metastatic disease and evaluation of the extent of metastatic disease in these high risk patients is crucial and has a major effect on a patient's prognosis, including choosing the necessary treatment and follow-up (9 
PATIENTS AND METHODS

Patients
Between January and December 2014, 17 consecutive patients (11 men, 6 women) with SDHB mutation-associated PHEOs/PGLs with a mean age of 40.3±14.0 years were prospectively evaluated at the Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) at the National Institutes of Health (NIH). All patients had proven metastatic PHEOs/PGLs based on clinical evaluation, including previously found and surgically removed PHEOs/PGLs, biochemical diagnosis, and anatomical and functional imaging.
The study protocol was approved by the institutional review board of the Eunice Kennedy Shriver NICHD (protocol: 00-CH-0093). All patients provided written informed consent for all clinical, genetic, biochemical, and imaging studies regarding PHEOs/PGLs.
Mean age at diagnosis of primary PHEO/PGL in these patients was 30.2±15.0 years. The average interval between diagnosis of a primary tumor and referral to the NIH was 4.5±3.8 years.
All 17 patients previously underwent resection of their primary PHEO/PGL. Individual patient characteristics are summarized in Table 1 .
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68 Ga]-DOTATATE in SDHB-related PHEOs/PGLs 11 of carbidopa were administered orally. All PET/CT scans were performed on a Siemens
Biograph-mCT 128 PET/CT scanner (Siemens Medical Solutions). PET imaging was obtained in 3D mode. PET images were reconstructed on a 256 x 256 matrix using an iterative algorithm provided by the manufacturer, which also uses time of flight (TOF). Low-dose CT studies for attenuation correction and anatomic co-registration were performed without contrast and used for anatomical localization only.
Analysis of Data
Ga]-DOTATATE PET/CT studies were each read independently by two nuclear medicine physicians blinded to all imaging and clinical data except for the diagnosis, sex, and age of the patient.
Maximal standardized uptake values (SUV max ) were determined and focal areas of abnormal uptake showing a higher SUV max than surrounding tissue were considered as lesions.
Discrepancies, which occurred in 6 lesions with a mean SUV of 6.2±5.6 in 4 patients, were solved by consensus review. In all other imaging studies, physicians were blinded to [ Figure 2 .
DISCUSSION
In this study, we evaluated [ We feel this modality will also be useful in determining the possible eligibility for PRRT in patients with SDHB-related PHEO/PGL.
Functional imaging agents are able to target PHEOs/PGLs through different mechanisms. Ga]-DOTATATE PET/CT can be used to determine which patients may benefit from PRRT, which would be a desirable new treatment option for these patients (7, 8) . While PRRT has not been specifically evaluated in SDHB-related PHEOs/PGLs yet, it has already been shown to lead to longer progression-free survival, mainly in gastroenteropancreatic NETs (18) but also in other metastatic NETs, including PHEOs/PGLs (35) . Unfortunately, PRRT is not approved by the United States Food and Drug Administration at present. In the meanwhile, the high sensitivity of [ 68 
Ga]-DOTATATE PET/CT in SDHB-
related metastatic PHEO/PGL suggests that these patients can be treated with cold SSTR analogs, including sandostatin LAR, lanreotide, or others. Although this approach has not yet been evaluated in PHEOs/PGLs, results using lanreotide in gastroenteropancreatic NETs (36) and individual reports of octreotide treatment in patients with head and neck PGLs support this approach (37, 38) . This could also be extremely useful for patients in whom the location or extension of a PHEO/PGL lesion(s) (especially skull base) cannot be accessed by any surgical approach.
The phenomenon of additional lesions appearing with [ that were not seen by other imaging studies has been reported before (15, 17) . Since histologic proof of these lesions in our study was not possible, these lesions have to be discussed as false positive lesions. On the other hand, there are also studies that have reported histological confirmation of SSTR-positive tumor tissue in such cases, which led to a treatment change in up to 60% of patients (39) .
Last, the high detection rate of [ 
